Cargando…

Drug-eluting beads bronchial arterial chemoembolization vs. conventional bronchial arterial chemoembolization in the treatment of advanced non-small cell lung cancer

PURPOSE: To compare the effectiveness and safety of drug-eluting bead bronchial artery chemoembolization (DEB-BACE) with conventional bronchial artery chemoembolization (cBACE) and provide a novel treatment option for advanced non-small cell lung cancer (NSCLC). METHODS: Patients with advanced NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Guocan, Shen, Yanqin, Chen, Liangliang, Xu, Xudong, Yang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435292/
https://www.ncbi.nlm.nih.gov/pubmed/37601792
http://dx.doi.org/10.3389/fmed.2023.1201468
_version_ 1785092067595124736
author Yu, Guocan
Shen, Yanqin
Chen, Liangliang
Xu, Xudong
Yang, Jun
author_facet Yu, Guocan
Shen, Yanqin
Chen, Liangliang
Xu, Xudong
Yang, Jun
author_sort Yu, Guocan
collection PubMed
description PURPOSE: To compare the effectiveness and safety of drug-eluting bead bronchial artery chemoembolization (DEB-BACE) with conventional bronchial artery chemoembolization (cBACE) and provide a novel treatment option for advanced non-small cell lung cancer (NSCLC). METHODS: Patients with advanced NSCLC underwent DEB-BACE or cBACE and were screened retrospectively. Progression-free survival (PFS) and overall survival (OS) were the primary outcome indicators, while technical success rate, objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) were the secondary ones. RESULTS: A total of 41 patients were enrolled in the study, 12 in the DEB-BACE group and 29 in the cBACE group, according to the treatment regimen. No patient achieved complete response. Eighteen patients achieved partial response (9 in each group), 15 patients achieved stable disease (3 in the DEB-BACE group and 12 in the cBACE group), and eight patients achieved progressive disease (all in the cBACE group) when treated for 2 months. The overall ORR and DCR were 43.9% (18/41) and 80.5% (33/41), respectively. ORR and DCR in the DEB-BACE group were 50.0% (9/12) and 100.0% (12/12), respectively, while ORR and DCR in the cBACE group were 31.0% (9/29) and 72.4% (21/29), respectively. Compared to cBACE, the ORR and DCR of DEB-BACE were significantly improved (p < 0.05). The median PFS was better in the DEB-BACE group than in the cBACE group (6.95 months vs. 3.20 months, respectively, Hazard Ratio [HR] = 0.416; p = 0.005). Furthermore, the median OS was significantly better in the DEB-BACE group than in the cBACE group (28.5 months vs. 22.5 months, respectively, HR = 0.316; p = 0.020). CONCLUSION: DEB-BACE has a good safety and therapeutic profile in advanced NSCLC and is superior to cBACE. DEB-BACE can be used as an alternative treatment option for advanced NSCLC, even in elderly patients.
format Online
Article
Text
id pubmed-10435292
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104352922023-08-18 Drug-eluting beads bronchial arterial chemoembolization vs. conventional bronchial arterial chemoembolization in the treatment of advanced non-small cell lung cancer Yu, Guocan Shen, Yanqin Chen, Liangliang Xu, Xudong Yang, Jun Front Med (Lausanne) Medicine PURPOSE: To compare the effectiveness and safety of drug-eluting bead bronchial artery chemoembolization (DEB-BACE) with conventional bronchial artery chemoembolization (cBACE) and provide a novel treatment option for advanced non-small cell lung cancer (NSCLC). METHODS: Patients with advanced NSCLC underwent DEB-BACE or cBACE and were screened retrospectively. Progression-free survival (PFS) and overall survival (OS) were the primary outcome indicators, while technical success rate, objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) were the secondary ones. RESULTS: A total of 41 patients were enrolled in the study, 12 in the DEB-BACE group and 29 in the cBACE group, according to the treatment regimen. No patient achieved complete response. Eighteen patients achieved partial response (9 in each group), 15 patients achieved stable disease (3 in the DEB-BACE group and 12 in the cBACE group), and eight patients achieved progressive disease (all in the cBACE group) when treated for 2 months. The overall ORR and DCR were 43.9% (18/41) and 80.5% (33/41), respectively. ORR and DCR in the DEB-BACE group were 50.0% (9/12) and 100.0% (12/12), respectively, while ORR and DCR in the cBACE group were 31.0% (9/29) and 72.4% (21/29), respectively. Compared to cBACE, the ORR and DCR of DEB-BACE were significantly improved (p < 0.05). The median PFS was better in the DEB-BACE group than in the cBACE group (6.95 months vs. 3.20 months, respectively, Hazard Ratio [HR] = 0.416; p = 0.005). Furthermore, the median OS was significantly better in the DEB-BACE group than in the cBACE group (28.5 months vs. 22.5 months, respectively, HR = 0.316; p = 0.020). CONCLUSION: DEB-BACE has a good safety and therapeutic profile in advanced NSCLC and is superior to cBACE. DEB-BACE can be used as an alternative treatment option for advanced NSCLC, even in elderly patients. Frontiers Media S.A. 2023-08-03 /pmc/articles/PMC10435292/ /pubmed/37601792 http://dx.doi.org/10.3389/fmed.2023.1201468 Text en Copyright © 2023 Yu, Shen, Chen, Xu and Yang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Yu, Guocan
Shen, Yanqin
Chen, Liangliang
Xu, Xudong
Yang, Jun
Drug-eluting beads bronchial arterial chemoembolization vs. conventional bronchial arterial chemoembolization in the treatment of advanced non-small cell lung cancer
title Drug-eluting beads bronchial arterial chemoembolization vs. conventional bronchial arterial chemoembolization in the treatment of advanced non-small cell lung cancer
title_full Drug-eluting beads bronchial arterial chemoembolization vs. conventional bronchial arterial chemoembolization in the treatment of advanced non-small cell lung cancer
title_fullStr Drug-eluting beads bronchial arterial chemoembolization vs. conventional bronchial arterial chemoembolization in the treatment of advanced non-small cell lung cancer
title_full_unstemmed Drug-eluting beads bronchial arterial chemoembolization vs. conventional bronchial arterial chemoembolization in the treatment of advanced non-small cell lung cancer
title_short Drug-eluting beads bronchial arterial chemoembolization vs. conventional bronchial arterial chemoembolization in the treatment of advanced non-small cell lung cancer
title_sort drug-eluting beads bronchial arterial chemoembolization vs. conventional bronchial arterial chemoembolization in the treatment of advanced non-small cell lung cancer
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435292/
https://www.ncbi.nlm.nih.gov/pubmed/37601792
http://dx.doi.org/10.3389/fmed.2023.1201468
work_keys_str_mv AT yuguocan drugelutingbeadsbronchialarterialchemoembolizationvsconventionalbronchialarterialchemoembolizationinthetreatmentofadvancednonsmallcelllungcancer
AT shenyanqin drugelutingbeadsbronchialarterialchemoembolizationvsconventionalbronchialarterialchemoembolizationinthetreatmentofadvancednonsmallcelllungcancer
AT chenliangliang drugelutingbeadsbronchialarterialchemoembolizationvsconventionalbronchialarterialchemoembolizationinthetreatmentofadvancednonsmallcelllungcancer
AT xuxudong drugelutingbeadsbronchialarterialchemoembolizationvsconventionalbronchialarterialchemoembolizationinthetreatmentofadvancednonsmallcelllungcancer
AT yangjun drugelutingbeadsbronchialarterialchemoembolizationvsconventionalbronchialarterialchemoembolizationinthetreatmentofadvancednonsmallcelllungcancer